If approved, where would giredestrant plus everolimus fit within your treatment sequencing for ER-positive, HER2-negative advanced breast cancer after progression on CDK4/6 inhibitor-based endocrine therapy?

What factors most influence your choice of oral SERD-based combination therapy in this treatment setting, including combinations such as elacestrant-based regimens and imlunestrant +/- abemaciclib? Jhaveri et al. DOI: 10.1200/JCO.2026.44.16_suppl.1016